Nazione: Regno Unito
Lingua: inglese
Fonte: VMD (Veterinary Medicines Directorate)
Phenylbutazone
Dechra Limited
QM01AA01
Phenylbutazone
Solution for injection
POM-V - Prescription Only Medicine – Veterinarian
Horses
Anti Inflammatory NSAID
Authorized
1994-08-26
Amended pages: December 2022 AN: 01547/2022 Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF VETERINARY MEDICINAL PRODUCT Equipalazone 200 mg/ml Solution for Injection. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance Phenylbutazone 200 mg/ml Excipients Benzyl Alcohol 0.015 ml For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless to pale yellow solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Horses and ponies. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the treatment of musculoskeletal disorders in horses and ponies where the anti-inflammatory and analgesic properties of phenylbutazone can offer relief against inflammation, pain and lameness (for example, osteoarthritis, acute and chronic laminitis, bursitis and carpitis). 4.3 CONTRAINDICATIONS The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment. Do not administer with other non-steroidal anti-inflammatory agents concurrently or within 24 hours of each other. Do not use in animals suffering from cardiac, hepatic or renal disease; where there is the possibility of gastrointestinal ulceration or bleeding; where there is evidence of a blood dyscrasia or of hypersensitivity to the product. Amended pages: December 2022 AN: 01547/2022 Page 2 of 5 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Discontinue treatment if no response is evident after four to five days treatment. The clinical effect of phenylbutazone can be evident for at least three days following cessation of administration. This should be borne in mind when examining horses for soundness. 4.5 SPECIAL PRECAUTIONS FOR USE (i) Special precautions for use in animals Use in any animal under six weeks of age or in aged animals may involve additional risks. If such use cannot be avoided, animals may require a reduced dosage and special clinical management. Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a risk of increased toxicity. Leggi il documento completo